Neoadjuvant chemoradiation in oesophageal cancer
Mené sur 366 patients atteints d'un cancer de l'œsophage ou de la jonction œso-gastrique de stade localement avancé et résécable, cet essai multicentrique évalue, du point de vue de la survie globale à 5 ans, l'intérêt d'ajouter une chimioradiothérapie néoadjuvante à un traitement chirurgical
The role of neoadjuvant chemoradiation is still under debate in resectable oesophageal cancer. In The Lancet Oncology, Joel Shapiro and colleagues report the long-term results from the landmark CROSS trial,1 the initial results of which were reported in 2012.2 After a median follow-up of 84·1 months (IQR 70·7–96·6), the authors confirm that in patients with resectable oesophageal or junctional cancer, their neoadjuvant chemoradiotherapy regimen (intravenous carboplatin and paclitaxel with concurrent radiotherapy) significantly improves 5-year overall and progression-free survival compared with surgery alone, with the same effect size as initially reported in 2012.
The Lancet Oncology , commentaire, 2014